Oramed Pharmaceuticals

Transforming Injectables into Oral Therapies

Health Tech & Life Sciences
Public on NASDAQ on Apr, 2006<br>Public on TASE on Jul, 2017<br>
Follow

Company Overview

Snapshot

Founded in March 2006 by Nadav Kidron and Miriam Kidron, Oramed Pharmaceuticals operates with 11–50 employees. The company has raised a total of $149.13M across 10 funding rounds and went public on NASDAQ in April 2006.

Business overview

Oramed Pharmaceuticals is a Health Tech & Life Sciences company focused on developing oral delivery solutions for drugs typically administered via injection. Its core technology, the proprietary POD platform, enables the oral administration of protein-based therapies. The company's flagship product is an oral insulin capsule, currently in advanced Phase 3 clinical trials, designed to treat type 2 diabetes. Oramed serves the pharmaceutical and healthcare industries, aiming to improve treatment accessibility and patient quality of life by transforming injectable medications into oral forms.

Strategic signal

In October 2024, Oramed Pharmaceuticals announced a restructuring of its debt with Scilex Holding Company. This strategic move indicates Oramed's active management of its financial relationships and portfolio, which could signal a focus on optimizing its balance sheet and resource allocation for future growth initiatives or clinical development programs.

Log in to access full profile ›

Company Intelligence Q&A

What is Oramed Pharmaceuticals' primary focus?
Oramed Pharmaceuticals focuses on developing oral delivery solutions for drugs that are currently administered via injection, utilizing its proprietary platform technology.
When did Oramed Pharmaceuticals go public on NASDAQ?
Oramed Pharmaceuticals went public on NASDAQ in April 2006.
What was a significant financial transaction for Oramed Pharmaceuticals in September 2023?
In September 2023, Oramed announced a $101,875,000 short-term senior secured note transaction with Scilex Holding Company.
What was the status of Oramed's oral insulin program in October 2025?
In October 2025, Oramed released a letter to shareholders highlighting developments in its oral insulin program, including the launch of a new U.S. trial, and noted strong returns from its diversified investment portfolio.
What was a key development for Oramed Pharmaceuticals in November 2022 regarding commercialization?
In November 2022, Oramed signed a definitive deal with Medicox to commercialize its oral insulin in South Korea.
Log in to access full profile ›

External links